Physician profile
Mark Gloger
NPI 1295723146
$4,292.82
in general payments reported to CMS, 2019-2025
33 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $135 · 2021: $383 · 2022: $604 · 2023: $664 · 2024: $860 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214 · Education: $35.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.72 |
| Education | $35.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,166.05 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.36 | 2019-2024 | Xifaxan, Plenvu |
| Pfizer INC. | $337.18 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.73 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $289.44 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $144.69 | 2019-2024 | Sucraid |
| Celgene Corporation | $113.93 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $105.26 | 2019-2025 | |
| Covidien Lp | $100.00 | 2019 | |
| Daiichi Sankyo INC. | $94.05 | 2022-2024 | Injectafer |
| Genzyme Corporation | $90.70 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $79.78 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $75.97 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $71.98 | 2020-2023 | Dificid, Zinplava |
| Regeneron Healthcare Solutions, INC. | $67.34 | 2022-2025 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $60.23 | 2022-2023 | Renflexis |
| Fresenius Kabi USA, LLC | $56.31 | 2023-2024 | Idacio |
| Ardelyx, INC. | $51.22 | 2025 | Ibsrela |
| Lilly USA, LLC | $43.12 | 2025 | Omvoh |
| Gilead Sciences, INC. | $40.46 | 2019-2025 | |
| Evoke Pharma, INC. | $39.70 | 2022-2025 | |
| Braintree Laboratories, INC. | $35.98 | 2019-2021 | |
| Ucb, INC. | $35.87 | 2019 | |
| Allergan, INC. | $35.73 | 2019-2020 | |
| Celltrion USA INC. | $35.34 | 2024 | Zymfentra |
| Fujifilm Healthcare Americas Corporation | $34.99 | 2025 | |
| Mauna Kea Technologies, INC. | $31.00 | 2024 | |
| Phathom Pharmaceuticals, INC. | $26.87 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $24.57 | 2025 | Rezdiffra |
| Vivus LLC | $23.81 | 2019 | |
| Redhill Biopharma INC. | $14.32 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.32 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gloger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.